Decoy Therapeutics CSO Barbara Hibner Receives 4,216-Share Award

What Happened

• Barbara Louise Hibner, Chief Scientific Officer of Decoy Therapeutics Inc. (DCOY), was granted 4,216 restricted shares on 2026-08-31. The Form 4 reports the acquisition as an award (transaction code A) at $0.00 (no cash exchanged).
• The filing notes 25% of the restricted stock vested immediately (about 1,054 shares); the remaining shares will vest in approximately equal monthly increments over the next 36 months under the company’s 2026 Equity Incentive Plan.

Key Details

• Transaction date: 2026-08-31; Filing date: 2026-09-02 (timely filing within required Form 4 window).
• Reported price: $0.00 (award/grant, not an open-market purchase).
• Shares granted: 4,216 restricted shares; immediate vesting: 25% (~1,054 shares); remainder vests monthly over ~36 months (per footnote F1).
• Shares owned after the transaction: not specified in the provided filing details.
• Footnote: Grant made under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan (see F1).

Context

• Restricted stock awards are compensation subject to vesting and typically indicate long-term incentive alignment rather than an immediate market buy/sell signal. Because most of the grant vests over time, any future sales or exercises would be reported separately.